Drugs / GL2702 GLARS-NF1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02072213 | Aug 2013 → Jan 2014 | — | GL Pharm Tech Corporation | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GL2702 GLARS-NF1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02072213 ↗ |